TRANSGENE (TNG)

TRANSGENE

Sell: €0.77|Buy: €0.774|Change: 0.00 (-0.26%)

Open

€0.775

Previous close

€0.773

Trade high

€0.776

Volume

32,792

Year high

€1.50

Year low

€0.53

Dividend yield

–

Market capitalisation

€213.74 mn

P/E ratio

10.79

ISIN

FR0005175080

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPP

Share price

Performance 15/04/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
TRANSGENE	+ 1.85
More...

Company profile

Transgene SA is a French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Its clinical-stage programs include a portfolio of viral vector-based immunotherapeutics. The flagshipprogram, TG4050, is an individualized therapeutic vaccine based on the myvac platform. The company also has other viral vector-based programs, including BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. In addition, it conducts discovery and preclinical work, aimed at developing novel immunotherapies.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.